Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brodalumab Induction and Maintenance in Chinese Patients with Plaque Psoriasis
NCT04614298Phase 4Withdrawn
- Sponsor
- Kyowa Kirin
- Start
- Jan 2021
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in plaque psoriasis comparing KHK4827 210 mg SC with Placebo SC (2 arms). Primary endpoint: Proportion of subjects achieving 75% improvement from baseline in Psoriasis Area and Severity Index at 12 weeks. Planned start Jan 2021; status: withdrawn.
02
Drugs
brodalumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04614298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04614298.